CVT Plans Regadenoson NDA Submission As Cardiac Stress Agent For 2006
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CV Therapeutics expects to wrap-up two Phase III trials of its selective A2A-adenosine receptor agonist regadenoson (CVT-3146) in the third and fourth quarters, in time for a 2006 NDA submission